Adriamycin versus adriamycin plus cis-diamminedichloroplatinum (DDP) in advanced transitional cell bladder carcinoma A Southwest Oncology Group studyGagliano, Robert, M.D.; Levin, Howard, M.D.; El-Bolkainy, M. Nabil, M.D., Ph.D.; Wilson, Henry E., M.D.; Stephens, Ronald L., M.D.; Fletcher, William S., M.D.; Rivkin, Saul E., M.D.; O'Bryan, Robert M., M.D.; Coltman, Charles A. Jr., M.D.; Saiki, John H., M.D.; Stuckey, W. J., M.D.; Balducci, Lodovico, M.D.; Bonnet, John D., M.D.; Dixon, Dennis O., Ph.D.American Journal of Clinical Oncology: April 1983 - Volume 6 - Issue 2 - p 215–218 ORIGINAL ARTICLE: PDF Only Buy Abstract Patients with advanced transitional cell bladder carcinoma were randomized to receive either adriamycin alone, or adriamycin plus DDP. Overall response (CR ± PR) was 8/41 (19%) for adriamycin alone versus 16/37 (43%) for the combination (p = 0.02). Median response duration was 14 weeks for adriamycin versus 25 weeks for the combination (p = 0.17). Median survival was 28 weeks on adriamycin versus 31 weeks on the combination (p = 0.82). Median survival of responders was 43 weeks, and for patients with stable disease it was 29 weeks. This was significantly better than for those with increasing disease at 15 weeks (p = 0.02). Increased frequency of leukopenia and gastrointestinal toxicity were seen with the combination. Cardiotoxicity and nephrotoxicity were not prohibitive. © Lippincott-Raven Publishers.